☆ 4.5 Article

Real-world Short-term Effectiveness of Ustekinumab in Crohn's Disease: Results from a Multicenter, Prospective Study in China

INFLAMMATORY BOWEL DISEASES (2022)

25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future

Geert R. D'Haens et al.

Summary: Anti-TNF antibodies have been used for 25 years, playing a crucial role in Crohn's disease treatment. Many questions about this treatment have been answered through long-term clinical use, and the past experiences have laid the foundation for the development of future therapies.

GUT (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy

Luc Manlay et al.

Summary: The study compared the short- and long-term effectiveness of vedolizumab and ustekinumab in Crohn's disease patients who had previously failed response to anti-TNF agents. The results showed that ustekinumab was more effective than vedolizumab in achieving corticosteroid-free clinical remission.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology